Nature Reviews Cancer contents August 2012 Volume 12 Number 8 pp 503-578

Advertisement
Roche's X-tremeGENE Transfection Reagents Transfect efficiently with low cytotoxicity - proven in 275 different cell types...over 130 cancer cells. Free sample and protocols at http://www.x-tremegene.roche.com For life science research only. Not for use in diagnostic procedures
TABLE OF CONTENTS
August 2012 Volume 12 Number 8		Advertisement
Impact Factor 37.545 *	In this issue Comment Research Highlights Reviews Perspectives Also this month  Featured article: Pushing the limits of targeted therapy in chronic myeloid leukaemia Thomas O'Hare, Matthew S. Zabriskie, Anna M. Eiring & Michael W. Deininger	Get the most from your NGS data with Sequenom’s MassARRAY® system • Validate from tens to thousands of samples across tens to hundreds of SNPs • Design you own assays against any SNP of interest • Run a variety of applications including genotyping, DNA methylation and somatic mutation analysis
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
World CTC brings together the leading clinical minds alongside pioneering drug developers and academics to discuss progress in this field. Join us at World CTC to learn how you can use CTC technology to optimize drug development and clinical management of your patients. Register today to harness the potential of CTCs in the Clinic. Register Now Download the brochure
Advertisement
Nature Reviews Cancer is the no. 1 monthly review journal in oncology*. Ensure your institution has access by recommending a subscription to your library!
Comment: Upper urinary tract urothelial cancers: where it is A:T Magali Olivier, Monica Hollstein, Heinz Hans Schmeiser, Kurt Straif & Christopher P. Wild p503 | doi:10.1038/nrc3311 Despite a ban on the use of plants of the Aristolochia genus in herbal medicine, as they contain known carcinogens, renal cancer attributable to the use of this plant seems to be more common than previously thought. Abstract | Full Text | PDF
RESEARCH HIGHLIGHTS Top Tumour microenvironment: The haves and the have nots p505 | doi:10.1038/nrc3330 Three papers show that hepatocyte growth factor (HGF)–MET signalling is an important determinant of therapeutic responses and can be induced through paracrine, autocrine and endocrine production of HGF. PDF Genomics: The great pretenders p506 | doi:10.1038/nrc3326 Arul Chinnaiyan and colleagues have attempted to map the position of pseudogenes that are expressed throughout the genome. PDF Microenvironment: Domino effect p506 | doi:10.1038/nrc3332 Joan Massagué and colleagues have identified a paracrine signalling network between tumour and stromal cells in breast cancer that seems to drive both metastasis and resistance to chemotherapy. PDF Breast cancer: Genes, genes everywhere... p507 | doi:10.1038/nrc3323 Recently published papers using massively parallel sequencing to look at mutations in breast cancer provide food for thought. PDF Tumour microenvironment: Field effect p508 | doi:10.1038/nrc3324 Knockout of the Notch effector Rbpjk in mesenchymal fibroblasts enhances the formation of squamous cell carcinomas of the skin in mice, and similar changes can be induced by exposure of human skin to ultraviolet A irradiation. PDF Therapeutics: Antitumour potential of catalytic DNA p508 | doi:10.1038/nrc3328 A new study shows that a catalytic DNA molecule might be an effective and safe treatment for some forms of skin cancer. PDF Tumour suppressors: At the hypusine of the crime p509 | doi:10.1038/nrc3325 An in vivo short hairpin RNA screen identifies tumour suppressor genes in commonly deleted regions in lymphoma. PDF Chromothripsis: Towards a mechanism p510 | doi:10.1038/nrc3327 Wigard Kloosterman, Edwin Cuppen and colleagues have evidence that chromothripsis might arise owing to clustered DNA double-strand breaks (DSBs) and nonhomologous repair mechanisms. PDF Microenvironment: Suppressing the rejection of pancreatic tumours p510 | doi:10.1038/nrc3329 Two papers show that KRAS-G12D-transformed pancreatic tumour cells produce GM-CSF, which recruits MDSCs to promote an immunosuppressive microenvironment. PDF Mechanotransduction: Catching the X-waves p510 | doi:10.1038/nrc3331 A paper published in Nature Physics has experimentally and mathematically modelled epithelial cell migration and identified mechanically generated waves that are important for cellular motility. PDF IN BRIEF Therapeutics: First STAT forward | Genomic instability: Divide and conquer | Therapeutics: Therapy targets ribosomal reliance | Tumour evolution: Mutable markers PDF Cancer JOBS of the week Post-doctoral position: Metabolic defects in cancer Inserm U970 Postdoctoral Researchers in Lung and Colon Cancer Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC) Postdoctoral Fellow in Cancer Biology Georgia Health Science University (Medical College of Georgia) Cardiff School of Medicine PhD Studentship: T cell Receptors in Cancer immunotherapy Cardiff School of Medicine Postdoctoral Research Scholar in Cancer Research Cancer Institute of New Jersey More Science jobs from Cancer EVENT Pancreatic Cancer: Translation of New Ideas 12.10.12 Ny, US More science events from
Advertisement
Precision Optical Filters and Coatings Chroma offers a broad range of catalog and custom filter designs for applications such as low-light fluorescence microscopy and cytometry; spectrographic imaging in optical microscopy; laser-based confocal and multi-photon instrumentation; and Raman spectroscopy. Visit online or call for individual applications support 800-824-7662.
REVIEWS		Top
Pushing the limits of targeted therapy in chronic myeloid leukaemia Thomas O'Hare, Matthew S. Zabriskie, Anna M. Eiring & Michael W. Deininger p513 | doi:10.1038/nrc3317 Although chronic myeloid leukaemia (CML) can be treated with tyrosine kinase inhibitors (TKIs) against BCR-ABL1, cure is not achieved in most cases. This Review provides an update on resistance to TKIs, and discusses strategies to target BCR-ABL1-independent resistance, which may be necessary to eliminate CML stem cells and advanced disease. Abstract | Full Text | PDF
Kinesins and cancer Oliver Rath & Frank Kozielski p527 | doi:10.1038/nrc3310 Kinesins — a family of molecular motors that travel unidirectionally along microtubule tracks — have emerged as potential targets for cancer drug development. As discussed in this Review, several compounds that inhibit mitotic kinesins have entered clinical trials and others are being developed, raising the possibility that the range of kinesin-based drug targets may expand in the future. Abstract | Full Text | PDF | Supplementary information
The rationale for targeting the LOX family in cancer Holly E. Barker, Thomas R. Cox & Janine T. Erler p540 | doi:10.1038/nrc3319 The family of lysyl oxidases (LOX) seem to have dichotomous roles in tumour progression: suppressing tumorigenesis and promoting metastasis. This Review discusses the functions of the LOX family and the rationale for targeting them. Abstract | Full Text | PDF
PERSPECTIVES		Top
TIMELINE The ERBB network: at last, cancer therapy meets systems biology Yosef Yarden & Gur Pines p553 | doi:10.1038/nrc3309 This Timeline article focuses on the ERBB network of receptor tyrosine kinases, which exemplifies how a constant dialogue between basic and clinical cancer research can lead to the development of both novel drugs and strategies to overcome acquired resistance. Abstract | Full Text | PDF
OPINION NRF2 and cancer: the good, the bad and the importance of context Michael B. Sporn & Karen T. Liby p564 | doi:10.1038/nrc3278 NFE2-related factor 2 (NRF2) has apparently contradictory roles in cancer. Activation of NRF2 contributes to the chemopreventive effects of various clinically used drugs against various diseases including cancer. However, NRF2 activity can also accelerate tumorigenesis in mouse models, thus highlighting a potential danger of NRF2 activation. This Opinion article discusses how these opposing roles might be reconciled. Abstract | Full Text | PDF
OPINION From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets Cheryl Eifert & R. Scott Powers p572 | doi:10.1038/nrc3299 How many of the changes identified in human cancer by genome sequencing are meaningful? And how can we exploit these massive data sets to yield new therapeutic targets? This article outlines five approaches that aim to discover oncogenic drivers, tumour dependencies and, ultimately, new cancer therapies from cancer genome data. Abstract | Full Text | PDF
Corrigendum: Developmental reprogramming of cancer susceptibility Cheryl Lyn Walker & Shuk-mei Ho p578 | doi:10.1038/nrc3334 Full Text | PDF
Advertisement
Feel like your paper is lost in a sea of submissions? Scientific Reports publishes your research quickly and efficiently, and makes it freely available to the global scientific community. Learn more with our one minute illustrative video.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.